Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...
The developer of a drug for the rare multiple system atrophy, Alterity will launch a pivotal phase III trial after a go-ahead ...
Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.
YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ...
Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Good morning, and welcome to Ocugen's webcast to discuss data from the first half of patients completing 1 year since ...
Objectives To determine the prevalence of cerebral atrophy in a multi-ethnic systemic lupus erythematosus (SLE) cohort and to ...
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results